Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Share Option Schemes

15 Feb 2012 07:00

RNS Number : 4324X
Imaginatik PLC
15 February 2012
 



15 February 2012

Imaginatik plc

("Imaginatik" or the "Company")

 

Share Option Schemes

 

Imaginatik plc (AIM: IMTK), a leading provider of enterprise innovation services including a range of technology products and consultancy, announces that the remuneration committee of the Board has approved changes to the terms of the existing share options issued by the Company.

 

There are currently 27,461,845 options outstanding under the Company's various share option schemes, of which 24,012,500 are held by directors and eligible employees. 12,006,250 of these options have now been cancelled and the exercise price of a further 12,006,250 options, which currently ranges from 2.0p to 2.55p, has been rebased to 1p per share. The mid-market price of the Company's ordinary shares as at close of business on 14 February 2012 was 0.42p.

 

In addition, the Company has awarded 64,425,000 new share options to directors and employees with an exercise price of 1p per share ("New Options"):

 

a. Matt Cooper, Shawn Taylor, Luis Solis and Nicholas Goss, each being an executive director of the Company, have been granted 17,500,000, 11,125,000, 7,500,000 and 5,000,000 options respectively. The grant of a higher number of options to Mr Cooper and Mr Taylor is in recognition of salary sacrifices on their part during the half-year to 30 September 2011. The share options for Mr Cooper and Mr Taylor will be a combination of options issued under The Imaginatik plc Enterprise Management Incentive Scheme ("EMI scheme") as well as unapproved options. The share options for Mr Goss will all be issued under the EMI scheme. The share options for Mr Solis shall be issued under the Imaginatik 2006 Stock Option Plan.

 

b. David Gammon, Simon Charles and Brian Hays, non-executive directors of the Company, have each been granted 2,000,000 share options. The share options for Mr Gammon and Mr Charles shall be issued as unapproved options, and those for Mr Hays shall be issued under the Imaginatik 2006 Stock Option Plan.

 

c. Key employees of the Company have been granted 17,300,000 share options under the EMI scheme as well as the Imaginatik 2006 Stock Option Plan.

 

The re-based options and the New Options will vest as to 50% two years after grant and 50% three years after grant, subject to certain events as particularised in the scheme rules.

 

The remuneration committee considers that the grant of the New Options and the combined re-basing and cancellation of existing options provides the senior management team and employees of the Company with an appropriate and effective incentive for the future.

 

In addition to the above grants, Northland Capital Partners Limited has been granted 3,206,451 options over new ordinary shares exercisable at any time at 0.5p per share expiring on 13 February 2017 (in connection with the recent placing and open offer).

 

Imaginatik now has 78,087,046 share options in issue, representing approximately 15.22% of the current issued share capital and 13.21% of the fully diluted share capital.

 

Executive Directors

Options

Matt Cooper

19,062,500

Shawn Taylor

14,225,000

Luis Solis

9,500,000

Nicholas Goss

5,000,000

Non-Executive Directors

David Gammon

2,000,000

Simon Charles

2,000,000

Brian Hays

2,000,000

Employees

17,643,750

Ex-employees

3,449,345

Northland Capital Partners

3,206,451

 

 

 

Matt Cooper, Shawn Taylor and Luis Solis, Executive Directors of the Company and Mr Andrew Wainwright, a former Executive Director of the Company, are participating in the re-basing of the existing share options to the extent of an aggregate of 8,537,500 options. The re-basing of the share options is deemed to be a related party transaction under the AIM Rules for Companies. Nicholas Goss, Brian Hays and David Gammon, the independent directors of the Company for the purposes of the transaction, having consulted with the Company's Nominated Adviser, Northland Capital Partners Limited, consider that the terms of the re-basing of the existing share options are fair and reasonable so far as the shareholders of the Company are concerned.

 

Matt Cooper, Executive Chairman of Imaginatik, commented, "Following a comprehensive review of the Company's share option schemes, we are pleased to have put in place a revised share option structure that we believe properly incentivises our employees to build the Company in the long term."

 

For further information please contact:

 

Imaginatik plc

Tel: 020 7917 2975

Matt Cooper, Executive Chairman / Shawn Taylor, CFO

Northland Capital Partners Limited

Tel: 020 7796 8800

Gavin Burnell / Edward Hutton

Newgate Threadneedle

Tel: 020 7653 9850

Caroline Evans-Jones / Hilary Millar

 

About Imaginatik

 

Imaginatik provides Innovation and Idea management solutions comprised of consultancy, software and program management to deliver innovation outcomes to companies such as The Chubb Group of Insurance Companies, Boeing, Pfizer, Goodyear, Paccar, Kellogg and Cargill. Few companies possess the internal capability to consistently generate fresh ideas, identify those worth pursuing and reliably transform them into real, value-enhancing assets. This is Imaginatik's area of expertise.

 

Imaginatik is a public company whose shares are traded on the AIM market of the London Stock Exchange (LSE:IMTK.L) and a World Economic Forum Technology Pioneer with offices in Boston, MA, and London. In 2009, Imaginatik was named as one of the 500 fastest growing technology companies in the EMEA region by Deloitte. For more information, visit www.imaginatik.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFVTFRISLIF
Date   Source Headline
28th Jul 20154:07 pmRNSHolding(s) in Company
24th Jul 201512:50 pmRNSHolding(s) in Company
21st Jul 20155:31 pmRNSHolding(s) in Company
20th Jul 20157:00 amRNSSubscription and Director Dealings
15th Jul 20157:00 amRNSFinal Results
10th Jul 20159:23 amRNSHolding(s) in Company
1st Jul 20157:00 amRNSContract Win
29th Jun 20155:11 pmRNSHolding(s) in Company
29th Jun 20155:10 pmRNSHolding(s) in Company
29th Jun 201510:30 amRNSHolding(s) in Company
25th Jun 20157:00 amRNSHolding(s) in Company
25th Jun 20157:00 amRNSHolding(s) in Company
23rd Jun 20155:15 pmRNSHolding(s) in Company
23rd Jun 20157:00 amRNSHolding(s) in Company
22nd Jun 20157:00 amRNSMarket Update
1st Jun 20152:38 pmRNSResult of General Meeting
15th May 20157:00 amRNSPosting of Circular
14th May 20157:00 amRNSProposed Issue of Equity
13th Apr 20157:00 amRNSContract Wins
30th Mar 20157:00 amRNSContract Extension
16th Feb 20157:00 amRNSContracts win
11th Feb 20158:05 amRNSTrading Update
19th Jan 20157:00 amRNSDirector Loan
22nd Dec 201410:30 amRNSGrant of Options
17th Dec 20147:00 amRNSFive Year Contract Win
16th Dec 20147:00 amRNSContract Win
8th Dec 20147:00 amRNSInterim Results
19th Nov 20147:00 amRNSDirectorate Change
14th Nov 201411:52 amRNSBlocklisting Interim Review
24th Oct 20147:00 amRNSIssue of Equity/Director's Dealing
7th Oct 20145:04 pmRNSDirector/PDMR Shareholding
27th Aug 201410:50 amRNSHolding(s) in Company
21st Aug 20141:31 pmRNSDirector/PDMR Shareholding
18th Aug 20141:37 pmRNSHolding(s) in Company
14th Aug 20141:38 pmRNSResult of AGM
22nd Jul 20147:00 amRNSProposed Share Consolidation and Notice of AGM
1st Jul 20147:00 amRNSFinal Results
16th May 201411:40 amRNSHolding(s) in Company
15th May 20148:50 amRNSBlocklisting Interim Review
13th May 201411:47 amRNSHolding(s) in Company
12th May 20144:14 pmRNSResult of General Meeting and Exercise of Options
25th Apr 20147:00 amRNSProposed Placing and Subscription
14th Apr 20147:00 amRNSContract Wins and Trading Update
18th Mar 20147:00 amRNSContract Wins
28th Feb 201410:35 amRNSDirector's Dealing
26th Feb 201412:39 pmRNSDirector's Dealing
19th Dec 20133:38 pmRNSHolding(s) in Company
18th Dec 20137:00 amRNSExercise and Grant of Options
13th Dec 20137:00 amRNSContract Extension
3rd Dec 20137:00 amRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.